Viamet Pharmaceuticals Initiates Phase 2 Clinical Program With Novel Antifungal Agent VT-1161
Published: Sep 06, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis (VVC) and is being conducted at leading clinical centers in the United States. VT-1161 has been shown in preclinical studies to potently inhibit in a selective manner a wide range of fungal pathogens causing human disease. In previous phase 1 clinical studies, VT-1161 demonstrated good safety, tolerability and pharmacokinetics.
Help employers find you! Check out all the jobs and post your resume.